Month: August 2022

Aug 23 2022

Uncategorized

Minerva Seeks FDA Approval For Schizophrenia Candidate

by Clinical Editor

No Comments

Minerva Neurosciences (NASDAQ: NERV) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roluperidone in the treatment of negative symptoms for patients with...

Aug 23 2022

Uncategorized

Schizophrenia and the College Years

by Clinical Editor

No Comments

Recognizing the first signs of a mental health disorder like schizophrenia is key to getting proper treatment. Unfortunately, most people aren’t trained to identify early warning cues. Symptoms like a...

Aug 23 2022

Uncategorized

Long-Acting Injectables decrease Disease Relapse in Schizophrenia: study

by Clinical Editor

No Comments

Clinicians should more broadly consider the long-term use of long-acting injectable antipsychotics for people with schizophrenia according to a recent study published in the JAMA Network Open.

Aug 23 2022

Uncategorized

Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy

by Clinical Editor

No Comments

MapLight Therapeutics has concluded a Phase I clinical trial of ML-007 for treating neurologic ailments such as schizophrenia and dyskinesia.

Aug 22 2022

Uncategorized

Schizophrenia and the College Years

by Clinical Editor

No Comments

Recognizing the first signs of a mental health disorder like schizophrenia is key to getting proper treatment. Unfortunately, most people aren’t trained to identify early warning cues. Symptoms like a...

Aug 22 2022

Uncategorized

Long-Acting Injectables decrease Disease Relapse in Schizophrenia: study

by Clinical Editor

No Comments

Clinicians should more broadly consider the long-term use of long-acting injectable antipsychotics for people with schizophrenia according to a recent study published in the JAMA Network Open.

Aug 22 2022

Uncategorized

Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy

by Clinical Editor

No Comments

MapLight Therapeutics has concluded a Phase I clinical trial of ML-007 for treating neurologic ailments such as schizophrenia and dyskinesia.

Aug 22 2022

Uncategorized

Karuna’s experimental schizophrenia drug succeeds in advanced study

by Clinical Editor

No Comments

If approved by the FDA, the Boston biotech’s medicine would be the first new type of treatment for the disease in decades.

Aug 22 2022

Uncategorized

Mattie’s Call: Man diagnosed with schizophrenia missing in South Fulton

by Clinical Editor

No Comments

A Mattie’s Call was issued on Friday for a missing man in South Fulton, authorities said. Curtis Bevly, who is 27 years old, was last seen in the 2500 block...

Aug 21 2022

Uncategorized

Schizophrenia and the College Years

by Clinical Editor

No Comments

Recognizing the first signs of a mental health disorder like schizophrenia is key to getting proper treatment. Unfortunately, most people aren’t trained to identify early warning cues. Symptoms like a...